Frankfurt - Delayed Quote EUR

Autolus Therapeutics plc (6A3A.F)

1.5200
+0.0600
+(4.11%)
At close: May 30 at 8:03:42 AM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Christian Martin Itin Ph.D. CEO & Director 2.29M -- 1964
Mr. Alex Driggs Senior VP of Legal Affairs & General Counsel and Secretary -- -- 1976
Dr. Christopher Williams Chief Business Officer -- -- 1980
Dr. Matthias Will M.D. Senior VP & Chief Development Officer -- -- 1973
Dr. Martin Pule M.D., MBBS Founder, Senior VP & Chief Scientific Officer -- -- 1972
Mr. Robert F. Dolski Senior VP, CFO & Principal Accounting Officer -- -- 1970
Mr. Christopher Vann Senior VP & COO -- -- 1965
Mr. David Brochu Senior VP & Chief Technical Officer -- -- 1956
Ms. Olivia Manser Director of Investor Relations -- -- --
Mr. Alexander Swan Senior VP & Chief Human Resources Officer -- -- 1965

Autolus Therapeutics plc

The Mediaworks
191 Wood Lane White City
London, W12 7FP
United Kingdom
44 20 3829 6230 https://www.autolus.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
647

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Corporate Governance

Autolus Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 14, 2025 at 5:00 AM UTC

Autolus Therapeutics plc Earnings Date

Recent Events